KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Operating Expenses (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 13 years of Other Operating Expenses data on record, last reported at $26.2 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 121.03% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $89.0 million, up 237.61%, while the annual FY2024 figure was $146.5 million, N/A changed from the prior year.
  • Other Operating Expenses reached $26.2 million in Q4 2025 per ACAD's latest filing, up from $21.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $26.2 million in Q4 2025 and bottomed at -$124.7 million in Q4 2024.
  • Average Other Operating Expenses over 5 years is $4.8 million, with a median of $7.1 million recorded in 2021.
  • The widest YoY moves for Other Operating Expenses: up 1276.78% in 2024, down 797.07% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $2.6 million in 2021, then dropped by 5.78% to $2.4 million in 2022, then skyrocketed by 641.44% to $17.9 million in 2023, then tumbled by 797.07% to -$124.7 million in 2024, then soared by 121.03% to $26.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $26.2 million in Q4 2025, $21.6 million in Q3 2025, and $20.7 million in Q2 2025.